Merck: CHMP grants positive opinions

(CercleFinance.com) - Merck and Eisai today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted several approvals.


The CHMP recommends approval of the combination of Merck's anti-PD-1 therapy KEYTRUDA and Eisai's orally available multi-receptor tyrosine kinase inhibitor LENVIMA for the treatment of advanced renal cell carcinoma (RCC) for two different indications, Merck said.

Decisions on the CHMP recommendations will be given by the European Commission for marketing authorisation in the EU and are expected in Q4 2021.
If approved, this would be the first combination of an anti-PD-1 therapy with a tyrosine kinase inhibitor approved for the treatment of two different cancer types in the EU, it added.


Copyright (c) 2021 CercleFinance.com. All rights reserved.